Halozyme Therapeutics (HALO)
(Real Time Quote from BATS)
$38.50 USD
-0.62 (-1.59%)
Updated Apr 25, 2024 03:37 PM ET
3-Hold of 5 3
B Value B Growth C Momentum A VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 27% (69 out of 251)Zacks Sector Rank
Top 19% (3 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.40 | 1.35 | 9.99 |
Current Quarter Estimate | 0.69 | 7.43 | 60.00 |
Year Ago Quarter Estimate | 0.47 | 0.12 | 52.54 |
Next Quarter Estimate | 0.73 | 7.81 | 61.00 |
Next Year Estimate | 4.52 | 37.76 | 270.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 32.85 | 12.90 | 17.08 |
Next Year | 22.83 | 8.30 | 8.00 |
Last 5 Years | NA | 1.00 | 8.10 |
Next 5 Years | 25.00 | 19.90 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 14.07 | -2.18 |
Price/Book (MRQ) | 61.66 | 2.01 |
Price/Cash Flow (MRFY) | 12.31 | 14.08 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 33.96% | -100.99% |
Return on Equity (TTM) | 248.20% | -55.59% |
Debt to Equity (MRQ) | NA | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.